Therefore, CD123 constitutes a promising target for AML (Baroni et al., 2020; Gill et al., 2014) for which multiple therapeutics are being explored preclinically and clinically including IL-3 bound to diphtheria toxin (Liu et al., 2004), monoclonal antibodies (mAb) blocking IL-3 (Roberts et al., 2010) or engineered for enhanced antibody-dependent cellular cytotoxicity (ADCC; Busfield et al., 2014), an ADC (Kovtun et al., 2018), and bispecific TCEs, e.g., a CSL362/OKT3-TCE (Chichili et al., 2015; Hutmacher et al., 2019). Here, IL3 is linked to acute myeloid leukemia.